Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Reports Results From Ongoing MosaiQ Performance Evaluation Studies and First Quarter Fiscal 2018 Financial Results
Latest performance evaluation studies confirm substantial concordance with predicate technologies for blood grouping and initial disease screening applications European field trials expected to be completed in CY17 Record reagent revenues recorded during the quarter, exceeding guidance Six new
View HTML
Toggle Summary Quotient Limited to Report Continued Progress on the Commercial Scale-Up of MosaiQ™ and Fiscal First Quarter 2018 Financial Results and Host Conference Call
JERSEY, Channel Islands, July 21, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that an update on the results of internal verification and validation studies for the MosaiQ™ system, as well as financial results for its fiscal
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference
JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June
View HTML
Toggle Summary Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results
Initial MosaiQ manufacturing system commissioned and validated First "commercially ready" MosaiQ Instrument delivered to Quotient Internal validation of MosaiQ underway , with EU field trials expected in 3QCY17 Fourth quarter revenues of $5.5 million and Product sales of $4.7 million, exceeding
View HTML
Toggle Summary Quotient Limited to Participate in the UBS Global Healthcare Conference
JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at
View HTML
Toggle Summary Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ended March 31, 2017 will be released after market close on Monday, May 22, 2017.
View HTML
Toggle Summary Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 10, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 8,050,000 of its ordinary shares at a price to the public of $6.00 per share, which includes the
View HTML
Toggle Summary Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 05, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 7,000,000 of its ordinary shares at a price to the public of $6.00 per share.
View HTML
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 04, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares. Jefferies LLC is acting as sole book-running manager and BTIG, LLC
View HTML
Toggle Summary Quotient Reports Continued Positive MosaiQ™ Performance Evaluation Results
Antibody Detection — enhanced detection versus predicate technologies Manufacturing of Microarrays for European field trials planned to commence in early April MosaiQ ™ instrument development completed and formal validation has commenced Completion of European field trials expected in
View HTML